DeTIL 0255
Alternative Names: DeTIL-0255; NX-0255; NX-DeTIL-0255-201Latest Information Update: 28 Jan 2025
At a glance
- Originator Nurix
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cervical cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for phase-I development in Cervical-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Endometrial-cancer(Late-stage disease, Recurrent, Second-line therapy or greater) in USA (Parenteral)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Fallopian-tube-cancer(Late-stage disease, Second-line therapy or greater) in USA (Parenteral)